1. Home
  2. Companies
  3. 1AI
  4. Material Events

Algorae Pharmaceuticals (ASX:1AI) — Material Events

ASX:1AI · 23 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 16 articles Notable 7 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
16
AlgoraeOS v2 Outperforms Google DeepMind in AI Drug Discovery UpgradeMedium
Algorae launches advanced AI drug discovery platform AlgoraeOS v2, outperforming Google DeepMind models
10 Nov 2025 ·ASX Announcement ·85
Algorae Launches Five Generic Oncology Drugs in ANZ via Exclusive Sakar DealMedium
Algorae inks exclusive licensing deal with Sakar to launch oncology generics in ANZ
23 Sept 2025 ·Commercial Agreement Announcement ·85
Algorae Pharmaceuticals Boosts Cash to $5.47M and Expands ANZ Commercial PlatformMedium
Algorae Pharmaceuticals boosts cash to $5.47M, expands commercial agreements, and advances AI drug validation
30 Apr 2026 ·Quarterly Activities Report & Appendix 4C ·85
AlgoraeOS v2 AI Platform Identifies 90 Promising CBD-Drug Combos, Outperforms DeepMindMedium
AlgoraeOS v2 AI platform identifies 90 promising CBD-drug combos, outperforms DeepMind
12 Dec 2025 ·ASX Announcement ·85
Algorae and Peter Mac Advance AI-Driven Cancer Drug Synergy ValidationMedium
Algorae Pharmaceuticals and Peter Mac launch second AI-driven drug synergy validation program
30 Mar 2026 ·Collaboration Agreement Announcement ·80
Algorae Pharmaceuticals Boosts AI Platform and Secures $3M for Commercial GrowthMedium
Algorae Pharmaceuticals advances AI drug discovery and commercial partnerships, secures $3M debt facility and raises $199K via options
28 Jan 2026 ·Quarterly Activities Report & Appendix 4C ·80
Algorae Expands AI Drug Combo Pipeline with 18 Anchors and 9 Million PredictionsMedium
Algorae expands AI drug combo pipeline with 18-anchor AOS2 program generating millions of synergy predictions
18 May 2026 ·Corporate Update ·80
Algorae Pharmaceuticals Accelerates AI Drug Discovery with Peter Mac PartnershipMedium
Algorae Pharmaceuticals advances AI drug platform, secures strategic partnership and commercial leadership
29 July 2025 ·Quarterly Activities and Cash Flow Report ·80
Algorae Pharmaceuticals Expands Generics Portfolio and Advances AI PlatformMedium
Algorae Pharmaceuticals expands commercial portfolio, advances AI platform, appoints new COO
28 Oct 2025 ·Quarterly Activities Report & Appendix 4C ·80
Algorae Secures Exclusive Deal with Zydus for 10 Medicines in ANZ MarketsMedium
Algorae and Zydus Lifesciences ink exclusive deal for 10 products in Australia and New Zealand
28 Apr 2026 ·Commercial Agreement ·80
Algorae Pharmaceuticals Narrows Losses and Advances AI-Driven Drug PipelineMedium
Algorae Pharmaceuticals narrows losses, advances AI drug platform and pipeline with new executive appointments
28 Aug 2025 ·Appendix 4E and Annual Report ·80
Algorae Expands Australian Oncology Reach with Dr. Reddy’s Capecitabine DealMedium
Algorae inks distribution deal with Dr. Reddy’s for Capecitabine in Australia
27 Nov 2025 ·Distribution Agreement Announcement ·75
Algorae Partners with Cadila to Launch Generics in Australia and New ZealandMedium
Algorae inks binding term sheet with Cadila to launch generics in Australia and New Zealand
20 Oct 2025 ·ASX Announcement ·75
Algorae Expands ANZ Portfolio with Cadila Cardiovascular Generics DealMedium
Algorae inks deal with Cadila to launch two generic cardiovascular and metabolic drugs in ANZ
9 Feb 2026 ·Licence & Supply Agreement Announcement ·75
Algorae Secures Multi-Year NSW Health Supply Contract with Rollout Starting Q4 2026Medium
Algorae awarded NSW Health public hospital supply contract with rollout starting Q4 2026
1 July 2026 ·Contract Award Announcement ·75
AlgoraeOS v1 Validated; New AI Platform Version Promises Smarter Drug CombosMedium
AlgoraeOS v1 validated in independent preclinical study; AlgoraeOS v2 launched with enhanced AI capabilities
5 Dec 2025 ·ASX Announcement ·75
Notable Score 50–74
7
Algorae Pharmaceuticals Launches Loyalty Options Offer to Boost R&D FundingMedium
Algorae Pharmaceuticals launches Loyalty Options Offer to raise up to $5 million for R&D and expansion
17 Nov 2025 ·Prospectus ·70
Algorae Advances Australian Market Entry with TGA Dossier AcceptanceMedium
Algorae Pharmaceuticals' TGA Registration Dossier Accepted, Advancing Commercialization
2 Apr 2026 ·Regulatory Update ·70
Algorae Pharmaceuticals Validates AlgoraeOS v2 with Enhanced Drug Synergy PredictionsMedium
Algorae Pharmaceuticals validates improved AlgoraeOS v2 drug synergy prediction platform with positive preclinical results
3 July 2026 ·Preclinical Validation Announcement ·70
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.